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ABSTRACT 
Objective: The aim of this study was to formulate and evaluate gastro retentive drug delivery system (GRRDS) using an effervescent approach for 
simvastatin.  
Methods: Floating tablets were prepared using directly compressible polymers hydroxypropyl methylcellulose (HPMC) K100M, HPMC K4M and 
carboxymethylcellulose sodium (NaCMC). The prepared tablets were subjected to pre-formulation studies like Compressibility index, Hausner ratio 
and post compression parameters like buoyancy/floating test and In vitro dissolution study. 
Results: Drug-excipient compatibility studies performed with the help of FTIR instrument indicated that there were no interactions. The DSC 
thermogram of the formulations revealed that crystalline form of simvastatin existed in the formulation which was confirmed by X-ray powder 
diffraction
Conclusion: The drug release rate and floating duration of tablets depended on the nature of the polymer and other added excipients. The release 
rate of the drug can be optimized by using different ratios of polymers and other excipients. The formulation F8 achieved the optimized batch and 
complied with all the properties of the tablets. 
. Dissolution studies indicated that there was a decrease in the drug release with an increase in the polymer viscosity. The tablets 
prepared with low-viscosity grade HPMC K4M exhibited short Buoyancy Lag Time and floated for a longer duration as compared with formulations 
containing high viscosity grade HPMC K100M. The ‘n’ value for dissolution studies for all the formulations was found to be in the range of 0.647 to 
0.975 indicating non-Fickian or anomalous drug transport.  
Keywords: GRRDS, Simvastatin, Polymers, Drug release 




Atherosclerosis is a general term describing any hardening (loss of 
elasticity) of the medium of large arteries (in Greek, "Arterio" meaning 
artery and "sclerosis" meaning hardening), is a condition in which 
fatty material collects along the walls of arteries. This fatty material 
thickens, hardens, and eventually blocks the arteries [1]. Simvastatin is 
a lipid-lowering agent that is derived synthetically from a 
fermentation product of Aspergillus terreus. After oral ingestion, 
simvastatin, which is an inactive lactone, is hydrolyzed to the 
corresponding β-hydroxyacid form. This is an inhibitor of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme 
catalyzes the conversion of HMG-CoA to mevalonate, which is an early 
and rate-limiting step in the biosynthesis of cholesterol. Also, it has 
been reported [2, 3] that simvastatin is more efficiently extracted by 
the liver than its corresponding hydroxy acid with subsequent 
minimization of systemic burden [4]. This suggests that compared to a 
conventional dosage form, a sustained/controlled release dosage form 
of simvastatin might provide similar or better efficacy [5]. 
One of the most feasible approaches for achieving a prolonged and 
predictable drug delivery in the GI tract is to control the gastric 
residence time (GRT), i.e. gastro retentive drug delivery system 
(GRRDS). GRRDS extend significantly the period of time over which the 
drugs may be released. They not only prolong dosing intervals but also 
increase patient compliance beyond the level of existing controlled 
release dosage form [6]. A number of approaches have been used to 
increase the GRT of a dosage form in stomach by employing a variety 
of concepts such as Floating Systems [7], Bio/Mucoadhesive Systems 
[8], and Swelling and expanding systems [9], High-Density Systems 
[10], Incorporation of passage delaying food agents [11], Ion exchange 
resins [12], and Osmotic regulated systems [13]. 
Matrix tablets based on hydroxyl propyl methylcellulose (HPMC 
K4M) have been developed [14]. Upon contact with gastric fluid, the 
system takes up water and swell. As the increase in volume is 
greater than the increase in mass during swelling, the densities of 
these devices decrease and the system starts to float after a short lag 
time. The influence of different processing and formulation 
parameters on the floating properties of matrix tablets has been 
studied [15, 16]. Reduced floating lag times could be achieved by 
reducing the compression forces (thus, increasing tablet porosities), 
increasing polymer molecular weights and increasing the particle 
sizes of the matrix-forming polymer [17]. 
The objective of this study was to develop and optimize GRRDS 
containing simvastatin as a gastric floating dosage form having a bulk 
density lower than that of gastric fluids so that it remains buoyant on 
the stomach contents. To achieve the objective, independent 
formulation variables such as a drug to total polymer ratio, the 
polymer to polymer ratio and different viscosity grades of HPMC 
(K4M, K100M), Carbopol and NaCMC were examined. The dependent 
variables such as floating time, release profile, hardness and the 
kinetics and mechanism of drug release for the formulations were 
studied. 
MATERIALS AND METHODS 
Materials 
Simvastatin USP was received as a gift sample from Krebs 
biochemicals and industries Ltd, Visakhapatnam, India. Carbopol 
71G, HPMC K100M and K4M, Citric Acid Anhydrous was received as 
a gift sample from Colorcon Asia Pvt. Ltd. Sodium CMC was 
purchased from SD Fine-chem Ltd., Mumbai. Avicel PH 102, DCP 
anhydrous, Aerosil 200, Sodium Bicarbonate, Magnesium stearate 
and Talc were purchased from Signet Chemical Corp.  
Preparation of gastro retentive tablets 
The composition of different formulations of simvastatin floating 
tablets is shown in table 1. Gastro retentive tablets containing 
simvastatin were prepared by direct compression technique using 
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variable concentrations of polymers like HPMC K100M, HPMC 
K4M, carbopol 71G and NaCMC. The respective ingredients (drug, 
polymer, and additives) were passed through a sieve no. 60 (250 
μm) and blended with a turbula mixer (Analytical Technology, 
Bangalore, India). All the batches were compressed on a 10-station 
tablet machine (Cadmach, Ahmedabad, India) with 7-mm flat 
round punches. Three batches were prepared for each formulation 
(table 1). 
  
Table 1: Composition of gastro retentive tablets of simvastatin 
Ingredients Sieve no Quantity/tablet in mg 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Simvastatin #40 60 60 60 60 60 60 60 60 60 
HPMC K100M #60 80 80 -- -- -- -- -- -- -- 
Carbopol 71G #40 20 -- -- -- -- -- -- -- -- 
Sodium CMC #60 -- 20 -- -- -- -- 80 20 20 
HPMC K4M #60 -- -- 30 60 60 80 -- 80 100 
Avicel PH 102 #40 42.8 42.8 36 54 -- 62.8 62.8 42.8 22.8 
DCP Anhydrous #40 -- -- -- -- 54 -- -- -- -- 
NaHCo #40 3 50 50 50 50 50 50 50 50 50 
Citric acid anhydrous #40 16 16 16 16 16 16 16 16 16 
Aerosil 200 #40 5.6 5.6 4 5 5 5.6 5.6 5.6 5.6 
Talc #40 2.8 2.8 2 2.5 2.5 2.8 2.8 2.8 2.8 
Magnesium stearate #40 2.8 2.8 2 2.5 2.5 2.8 2.8 2.8 2.8 
Total(mg) -- 280 280 200 250 250 280 280 280 280 
Punch Size (mm) -- 9 9 7 8 8 9 9 9 9 
 
Infrared spectroscopy 
The infrared spectra of simvastatin and formulation were recorded 
on FTIR (JASCO-FTIR 5300). The samples were prepared on KBr 
press (Spectra Lab, Mumbai, India). 
Flow properties of granules 
The flow properties of granules were characterized in terms of angle 
of repose, Carr’s consolidation index and Hausner ratio.  
DSC (Differential scanning calorimetry) 
The instrument used was Perkin-Elmer DSC-7. Samples were sealed 
hermetically in a flat bottom aluminum cells. These samples were 
then heated over a temperature range of 320 °K-520 °K in an 
atmosphere of nitrogen (20 mm/min) at a constant rate of 5 °C/min 
with alumina being reference standard. 
X-ray diffraction 
The physical state of simvastatin in the various preparations was 
evaluated by X-ray diffraction. Powder X-ray diffraction patterns of 
all samples were determined using Phillips PW 3710 scanner, IW 
1830 generator with a CuK α anode at 40 kV and 30 mA and at a 
scan rate of 1 ° min-1 from 2θ range from 5 ° to 40 °. 
Buoyancy/floating test  
The time between introduction of the dosage form and its buoyancy on 
the simulated gastric fluid and the time during which the dosage form 
remain buoyant were measured. The time taken for the dosage form to 
emerge on the surface of the medium is called Floating Lag Time (FLT) 
or Buoyancy Lag Time (BLT) and total duration of time for which 
dosage form remain buoyant is called Total Floating Time (TFT) [18]. 
Effect of hardness on buoyancy lag time (BLT) or floating lag 
time (FLT)  
Formulation F8 was selected to study the effect of hardness on 
buoyancy lag time. The tablets of batch F8 were compressed at three 
different compression pressures to get the hardness of 4 kg/cm2, 5 
kg/cm2, 7 kg/cm2 and 8 kg/cm2
Drug release profile was evaluated in-vitro by using a dissolution 
test apparatus (Electro Lab, TDT-08L, Mumbai, India). The USP XXIII 
Type II (paddle-type) method was selected to perform the 
dissolution profile of simvastatin. The dissolution for all the 
formulations was carried out in 900 ml 0.1 N HCl containing 0.5 % 
SLS. The temperature was maintained at 37±0.5 °C and a constant 
paddle rotation speed of 50 rpm. Samples (10 ml) were withdrawn 
at regular intervals and filtered through a membrane filter (pore size 
0.22 μm). Each sample was analyzed at 239.1 nm using UV-visible 
spectrophotometer against reagent blank [21]. 
RESULTS AND DISCUSSION  
In the present study the floating tablets of simvastatin were 
prepared by direct compression technique with HPMC K4M, HPMC 
K100M, NaCMC, Carbopol as matrix polymers, sodium bicarbonate 
and citric acid anhydrous were used as a gas generating agent, MCC 
and DCP were used as a diluents, magnesium stearate and talc as a 
lubricant and glidant respectively. 
Drug-polymer interaction study 
Drug-polymer interaction studies were performed using FTIR 
spectrophotometer. Characteristics peaks obtained for the pure drug 
correlated well with that of the formulation peaks. This indicated 
that the drug was compatible with the formulation components. The 
FTIR spectra’s for the formulation and pure drug is shown in fig. 1. 
The FTIR spectra’s of all samples are shown in fig. 1. The spectrum 
of pure drug and formulation F-8 presented characteristic peaks at 
3553 cm
. And were evaluated for Buoyancy Lag 
Time by following the method as done for Buoyancy test [19, 20]. 
In vitro dissolution study 
-1 (alcohol O-H stretching vibration), 3011 cm-1 (olefinic C-H 
stretching vibration), 2957 and 2878 cm-1(methyl and methylene C-
H asymmetric and symmetric stretching vibration), 1719 cm-1 and 
1701 cm-1 (Lactone C=O and ester C=O stretch), 1453, 1406, and 
1383 cm-1(methyl and methylene bending vibration), 1267, 1222, 
1178, and 1080 cm-1 (lactone and ester C-O-C bending vibration), 
1060 cm-1 (secondary alcohol C-O stretching vibration), and 879 cm-
1
Powder X-ray diffractograms of pure simvastatin and formulation F-
8 are shown in fig. 3. The presence of numerous distinct peaks in the 
x-ray diffraction spectrum indicated that simvastatin was present as 
a crystalline material with major characteristic diffraction peaks 
appearing at a diffraction angle of 2θ at 7.72, 8.22, 10.81, 14.82, 
15.47, 16.39, 17.12, 17.57, 18.69, 19.28, 21.93, 22.52, 25.80, 28.24 
and 31.91. Formulation F-8 showed similar major characteristic 
diffraction peaks indicating the existence of simvastatin in 
crystalline form in the formulation F-8. 
(trisubstituted olefinic C-H wag), respectively. 
Differential scanning calorimetry (DSC) 
To understand the physical state of the drug, DSC was performed on 
pure drug and formulation F-8 (fig. 2). The DSC thermogram of the 
formulations revealed that an endothermic peak of melting of 
simvastatin at about 134.76 °C was shifted to about 133.97 °C. This 
suggested that a crystalline form of simvastatin existed in the 
formulation. 
X-ray diffraction 
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Fig. 1: Comparison of characteristic absorption peaks of simvastatin and formulation-F8 
 
 
Fig. 2: DSC thermograms of pure drug simvastatin and formulation F8 
 
 
Fig. 3: XRD patterns of pure drug simvastatin and formulation F8 
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Flow properties of granules  
The granules prepared for compression of floating tablets were 
evaluated for their flow properties (table 2). The angle of repose was 
in the range of 26.61 to 28.86 ° with granules containing HPMC 
K100M and 24.31to 32.60 ° with HPMC K4M. Bulk density ranged 
between 0.462 to 0.503 gm/cm3 with granules containing HPMC 
K100M and 0.408 to 0.536 gm/cm3 with HPMC K4M. Tapped density 
ranged between 0.552 to 0.563 gm/cm3 with granules containing 
HPMC K100M and 0.478 to 0.677 gm/cm3
 
 with HPMC K4M. Carr 
consolidation index was found to be 6.02 to 13.59 and Hausner ratio 
ranged from 0.84 to 1.33 for granules of different formulations. 
These values indicated that the prepared granules exhibited good 
flow properties. 
Table 2: Flow properties of granules 
Code Bulk density (g/cm3 Tapped density (g/cm) 3 Angle of repose (θ)* ) Carr’s consolidation index Hausner ratio 
F1 0.462 0.552 26.61±0.252 ° 11.83 1.17 
F2 0.503 0.563 28.86±0.352 ° 9.90 1.11 
F3 0.455 0.535 24.31±0.482 ° 13.59 1.15 
F4 0.486 0.531 26.77±0.285 ° 9.51 1.11 
F5 0.408 0.482 26.56±0.317 ° 9.96 0.84 
F6 0.433 0.478 26.85±0.159 ° 10.96 0.84 
F7 0.512 0.662 32.60±0.269 ° 13.2 1.33 
F8 0.536 0.677 29.86±0.421 ° 6.02 1.26 
F9 0.451 0.516 28.66±0.376 ° 9.10 0.90 
*n=3, Data presented as mean±SD. Rest of the values are given as mean of triplicate. 
 
Buoyancy/floating test  
On immersion in 0.1N HCl solution (pH 1.2), 0.5% SLS at 37 °C, the 
tablets floated and remained buoyant without disintegration. Table 
3 shows the results of Buoyancy study. From the results, it was 
concluded that the batch F1and F2 showed good Total floating time 
(TFT). Formulation F4 and F5 showed good BLT while the 
formulation F3 and F7 showed less TFT. And the formulation F8 and 
F9 showed good BLT as well as good TFT. All the batches of tablets 
were found to exhibit short BLT due to the presence of sodium 
bicarbonate and citric acid. The tablets with low-viscosity grade 
HPMC K4M exhibited short BLT and floated for a longer duration as 
compared with formulations containing high viscosity grade HPMC 
K100M. Increasing the concentration of HPMC K4M level in the 
formulations F3, F4, F5, F6, F8, and F9 prolonged the BLT and the 
total floating time. Thus a combination of sodium bicarbonate (50 
mg) and citric acid (16 mg) with HPMC K4M and HPMC K100M was 
found to achieve the optimum in vitro buoyancy and float ability. 
 
Table 3: Buoyancy lag time and total floating time 
Formulations Buoyancy lag time (Sec)* Total floating time (h)* 
F1 82±2.32 11.32±0.02 
F2 92±1.85 11.45±0.05 
F3 28±2.15 6.15±0.1 
F4 36±2.68 8.52±0.08 
F5 40±1.92 8.33±0.05 
F6 58±3.18 9.15±0.04 
F7 126±2.65 5.27±0.06 
F8 72±2.54 9.16±0.05 
F9 80±1.69 10.21±0.07 
*n=3, Data presented as mean±SD 
 
Effect of hardness on buoyancy lag time (BLT) or floating lag 
time (FLT)  
The effect of hardness on buoyancy lag time for batch F8 was 
studied. The results of floating lag time of tablets with hardness of 4 
kg/cm2, 5 kg/cm2, 7 kg/cm2 and 8 kg/cm2 were 73, 89, 118 and 167 
sec respectively. It can be concluded that as the hardness increases, 
the buoyancy lag time also increases linearly. The optimum 
hardness for the GRRDS was found to be 4-5 kg/cm2
The release data obtained for all the formulations is shown in fig. 
4. The release of drug from the formulations containing HPMC 
K100M (F1 and F2) showed very slow drug release whereas 
tablets containing only HPMC K4M showed complete drug release 
within 10 h. A formulation containing only NaCMC (F7) showed 
good release rates at the initial hour but failed to maintain matrix 
integrity and disintegrated rapidly. Formulations containing both 
HPMC K4M and NaCMC polymers were found to be more sustained 
(F8 and F9). These findings are in agreement with the earlier 
report [22]. It was found that a combination of anionic NaCMC 
with nonionic HPMC produced a synergistic increase in viscosity. 
This was attributed to the stronger hydrogen bonding between the 
carboxyl groups of NaCMC and hydroxyl groups of the HPMC, 
leading to stronger cross-linking between two gums. To confirm 
the exact mechanism of drug release from these tablets, the data 
were fitted according to the equation of Korsmeyer and Peppas, 
given as M
. 
In vitro dissolution study 
t/M∞ =Ktn where Mt/M∞ is the fractional release of drug 
in time t, K is a constant incorporating structural and geometric 
characteristics of the controlled-release device, and n is the 
diffusional release exponent indicative of mechanism of release. 
The value of n is 0.5 for Fickian transport, more than 0.5 and less 
than 1 for non-Fickian transport, and 1 for case II transport (zero 
order); when the value of n approaches 1, it may be concluded that 
the release is approaching zero order. The dissolution data were 
fit to the above equation by drawing a log-log plot of the fraction 
released versus time. The ‘n’ value was between 0.647 to 0.975, 
which indicated that the release followed non-Fickian diffusion 
mechanism or anomalous transport and suggesting that both 
diffusions of the drug in the hydrated matrix and chains relaxation 
process affect the drug release process (table 4). The initial burst 
effect is probably due to the fact that the gel layer, which controls 
the release of the drug, needs some time to become effective. The 
mixture of the two polymers, used as release modulator agents, 
enables the system to reach a nearly zero-order release kinetic (n 
for F8 is 0.975). 
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Fig. 4: Dissolution behaviour of the formulations n=3, Data presented as mean±SD 
 
Table 4: Regression values for zero order and first order of all the formulations 
Formulation Zero order First order Higuchi model  Peppas model 
r K value 2 r K value r n value 2 r2 
F1 0.991 1.103 0.989 0.011 0.986 0.767 0.990 
F2 0.990 1.420 0.988 0.013 0.988 0.679 0.991 
F3 0.990 11.31 0.975 0.276 0.987 0.627 0.981 
F4 0.994 6.482 0.954 0.122 0.986 0.648 0.995 
F5 0.995 6.238 0.965 0.112 0.983 0.743 0.994 
F6 0.996 5.491 0.975 0.087 0.980 0.804 0.995 
F7 0.997 11.79 0.905 0.421 0.997 0.432 0.977 
F8 0.998 7.768 0.877 0.244 0.993 0.593 0.999 
F9 0.998 7.438 0.943 0.172 0.992 0.664 0.996 
 *n=3, Average of three determinations 
 
CONCLUSION 
The concept of formulating GDDS containing simvastatin offers a 
suitable, practical approach to achieving a prolonged therapeutic 
effect by continuously releasing the medication over an extended 
period of time (10 h). This study discusses the preparation of GDDS 
of simvastatin; the effervescent based floating drug delivery system 
was a promising approach to achieve in vitro buoyancy. The drug 
release rate and floating duration of tablets depend upon the nature 
of the polymer and other added excipients. Thus, the release rate of 
the drug can be optimised by using different ratios of polymers and 
other excipients. The formulation F8 achieved the optimized batch 
and complied with all the properties of the tablets. 
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